Successful nilotinib therapy in a CML affected patient with A380T, P407S and V468A mutations, and a previous suboptimal cytogenetic response to imatinib

Successful nilotinib therapy in a CML affected patient with A380T, P407S and V468A mutations, and a previous suboptimal cytogenetic response to imatinib

Authors

  • Fabio Stagno Sezione di Ematologia, Dipartimento di Scienze Biomediche, Università di Catania
  • Alessandra Cupri Sezione di Ematologia, Dipartimento di Scienze Biomediche, Università di Catania
  • Stefania Stella Sezione di Patologia Generale, Dipartimento di Scienze Biomediche, Università di Catania
  • Michele Massimino Sezione di Patologia Generale, Dipartimento di Scienze Biomediche, Università di Catania
  • Silvia Rita Vitale Sezione di Patologia Generale, Dipartimento di Scienze Biomediche, Università di Catania
  • Paolo Vigneri Sezione di Patologia Generale, Dipartimento di Scienze Biomediche, Università di Catania

DOI:

https://doi.org/10.7175/cmi.v4i6S.1097

Keywords:

Nilotinib, Chronic myeloid leukemia, Therapy, Tyrosine kinase inhibitors

Abstract

Imatinib mesylate (IM) has shown unprecedented effectiveness in the treatment of Chronic Myeloid Leukemia (CML) patients (pts) in the chronic phase of the disease. However, some pts fail to respond or lose their initial response to IM. The European LeukemiaNet (ELN) published recommendations designed to identify patients responding poorly to imatinib. Here we report a case of a suboptimal cytogenetic responder to IM who had a successful response to the second generation tyrosine kinase inhibitor nilotinib (NIL). According to the ELN criteria, CML pts on IM-therapy might show a suboptimal response either because of failure to achieve a CCyR by 12 months of therapy or because of lack of a MMR after 18 months. The prognostic value of these two types of responders might be very different.

Downloads

Published

2015-10-13

Issue

Vol. 4 No. 6S (2010)

Section

Case report

License

Authors who publish with this journal agree to the following terms:
    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
    4. Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)